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Abstract
Background: The current study was conducted to examine the activity of a docetaxel/oxaliplatin (DocOx)
combination as second line treatment for advanced pancreatic ductal adenocarcinoma (Trial registration:
NCT00690300. Registered June 2, 2008)
Methods: DocOx is a prospective, multi-center, single arm, phase II trial using docetaxel (75 mg/m2, 60 min, d 1) and
oxaliplatin (80 mg/m2, 120 min, d 2) in 21-day cycles. The treatment period was scheduled for up to 8 cycles. Primary
endpoint was tumor response according to RECIST 1.0. Secondary endpoints were progression free survival, overall
survival, safety/toxicity, quality of life and clinical benefit.
Results: Data represent the intention to treat analysis of 44 patients with chemorefractory pancreatic cancer enrolled
between 2008 and 2012 at five institutions in Germany. The primary endpoint of tumor response was achieved in
15.9 % of the patients (7 partial remissions, no complete remission), with a disease control rate of 48 % after the first
two treatment cycles. Median progression free survival (PFS) was 1.82 months (CI 95 % 1.5–3.96 months) and median
overall survival (OS) was 10.1 months (CI 95 % 5.1–14.1 months).
Conclusions: This single-arm trial demonstrates that the combination of docetaxel and oxaliplatin yields promising
results for the treatment of advanced pancreatic ductal adenocarcinoma patients. Selected patients had particular
benefit from this treatment as indicated by long PFS and OS times. Even after 8 cycles of treatment with DocOx a
partial response was observed in 2 patients and stable disease was observed in another 6 patients. The data obtained
with the DocOx protocol compare well with other second line protocols such as OFF (oxaliplatin, 5-FU, leucovorin). The
DocOx regimen could be an interesting option for patients who received gemcitabine as first line treatment for
metastatic pancreatic cancer.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is a major
cause of cancer related deaths in the Western world.
The only curative option for PDAC is surgery, but at
the time of primary diagnosis only 10–15 % of patients
are eligible for surgery with curative intent. The main
limitation is the delayed diagnosis at an already locally
advanced or metastatic state of the disease [1, 2]. Con-
sequently, systemic therapy is the treatment of choice
for the majority of patients. The standard of care in
this setting has developed over the last decade. FOL-
FIRINOX and the combination of gemcitabine/nab-
paclitaxel have proven to be superior to single agent
gemcitabine in the first-line therapy of metastatic
PDAC [3, 4]. Second line strategies in PDAC achieve a
median progression free survival (mPFS) of 4 months
and a median overall survival (mOS) of 6 months,
respectively [5]. However, the optimal second-line strategy
for PDAC still remains to be defined [6, 7]. Compared to
best supportive care (BSC) or 5-fluorouracil (5-FU) alone
the combination of 5-FU, leucovorin and oxaliplatin
(OFF) significantly prolonged the overall survival time in
ECOG 0–2 (Eastern Cooperative Oncology Group) pa-
tients [8, 9]. Recently, the combination of nanoliposomal
irinotecan plus 5-FU has also shown superiority as second
line treatment for PDAC compared to 5-FU alone (mPFS
3.1 versus 1.5 months, HR 0.56; mOS 6.1 versus
4.2 months, HR 0.67) [10]. The objective response rate is
generally low in the second line setting [11]. Single agent
docetaxel achieves response rates of up to 15 % as first
line therapy of advanced PDAC [12, 13], and has moderate
activity as second line treatment of PDAC in retrospective
analyses [14, 15]. Oxaliplatin-based combination regimen
show similar response rates as docetaxel [16–18]. Several
phase I/II studies confirmed the efficacy and safety of the
combination of docetaxel plus oxaliplatin for different
tumor entities [19–21]. To date the combination of both
substances has not been evaluated in the treatment of che-
morefractory PDAC. The current study was conducted to
prospectively evaluate the activity and feasibility of the
combination of docetaxel/oxaliplatin (DocOx) as second
line treatment of PDAC.
Patients and methods
The DocOx trial (NCT00690300) was designed as an
open label, multicenter, single arm, phase II study.
Between February 2008 and March 2012, 47 patients
were enrolled at five German institutions. The final ana-
lysis was restricted to 44 patients.
Patient population
Inclusion criteria were as follows: histologically or
cytologically confirmed metastatic or unresectable locally
advanced PDAC; age ≥18 years; at least one measurable
target lesion according to RECIST 1.0 (Response Evaluation
Criteria in Solid Tumors) outside any previously irradiated
area; failure of first line therapy of metastatic or unresect-
able locally advanced PDAC due to progressive disease
during or within 3 months after finishing first line chemo-
therapy; Karnofsky performance score (KPS) >60 % (ECOG
0–2); life expectancy ≥12 weeks; adequate bone marrow
function (granulocyte count ≥1.5x109/L, platelet count
≥100x109/L, hemoglobin ≥9 g/dl); serum bilirubin
levels <2 times upper limit of normal (ULN), up to 2.5
times ULN in case of hepatic metastasis (biliary drain-
age allowed); transaminases <2.5 times ULN.
Exclusion criteria were as follows: Any other primary
tumor or secondary malignancy except basal cell carcin-
oma of the skin or in situ carcinoma of the cervix uteri
(patients with adequately treated other malignancies and
tumor absence for ≥5 years were eligible); pregnancy or
breastfeeding period; patients unable to ensure adequate
contraception; known cerebral metastasis; uncontrolled
severe infections; peripheral neuropathy exceeding
CTCAE (Common Terminology Criteria for Adverse
Events) grade 1.
All patients signed a written informed consent
according to national and local regulations. The proto-
col was approved by the Ethics Committee of Ulm
University [22].
Treatment plan
In this open label trial patients received docetaxel
75 mg/m2 (60 min iv infusion) on day 1 and oxaliplatin
80 mg/m2 (120 min iv infusion) on day 2, repeated every
3 weeks. Treatment was administered at least for 8 -
cycles, unless there was tumor progression, unacceptable
toxicity or patient refusal. In case of stable disease (SD)
after 8 cycles patients could choose to carry on with the
therapy. Premedication included adequate antiemetic
therapy and oral dexamethasone 8 mg the day prior to
docetaxel application as well as on days 2 and 3 after do-
cetaxel treatment. On treatment days the patients re-
ceived another 16 mg of dexamethasone iv. To prevent
oxaliplatin related polyneuropathy 1 g calcium gluconate
and 1 g magnesium gluconate were administered iv prior
to and after oxaliplatin infusion. In case of severe hema-
totoxicity prophylactic granulocyte colony-stimulating
factor treatment in addition to dose modification was
applied. In case of neutropenia <1.5x109/L, thrombope-
nia <100x109/L, diarrhea > grade 1, peripheral neur-
opathy > grade 1 or other nonhematologic toxicities >
grade 1 treatment could be delayed up to a maximum of
2 weeks. In case of a 2 weeks delay and ongoing
neutropenia the dose of both cytostatics was reduced to
50 % if neutrophiles were 1.0 to 1.5x109/L or if platelets
were 50 to 100x109/L. Treatment was discontinued in
case of neutropenia <1.0x109/L, thrombopenia <50x109/
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L, peripheral neuropathy grade 2 or other ongoing non-
hematologic toxicities after 2 weeks delay. The dose of
both drugs was reduced to 80 % if granulocytes were less
than <0.5x109/L or <1.0x109/L with fever exceeding
38.5 °C, if platelets were <50x109/L or in case of non-
hematologic toxicity > grade 2 (except alopecia, nausea
and vomiting). In case of peripheral neuropathy grade 2
oxaliplatin was reduced to 50 % and docetaxel to 80 %
of the previous dose level after recovery. Toxicity was
assessed using the National Cancer Institute (NCI) com-
mon toxicity criteria (CTC) version 3. Repeated severe
toxicity after the second dose adjustment resulted in
termination of the treatment.
Pretreatment evaluation and follow-up
The baseline evaluation included a complete medical
history, physical examination including vital signs, an
electrocardiogram (ECG), complete blood count (CBC)
plus serum chemistry and, in case of child-bearing age, a
pregnancy test, all within one week prior to start of
treatment. A chest x-ray and abdominal computed tom-
ography were required to define the target lesion(s). All
patients received questionnaires to assess quality of life
(EORTC QLQ-C30) and clinical benefit (pain, use of
analgesics, body weight, Karnofsky performance score)
prior to each treatment cycle, furthermore the clinical
benefit was recorded weekly within each cycle. Assess-
ments before start and then weekly within each cycle
included physical examination, CBC plus serum chemis-
try and recording of adverse events. Tumor response
was evaluated by computed tomography after every sec-
ond cycle according to RECIST 1.0 for the defined target
lesions. Planned study termination after 8 cycles was
followed by six- weekly examinations including assess-
ment of life status, physical examination and Karnofsky
performance score. The treatment was stopped in case
of progressive disease, inacceptable toxicity, incompli-
ance, or patient’s wish.
Treatment evaluation
The primary endpoint of the study was defined as tumor
response according to RECIST 1.0. Toxicities were graded
according to NCI CTC version 3.0 Severe adverse events
(SAE) were defined as follows: any reaction, side effect or
disease displaying an increased risk or danger for the
patient. Quality of life was assessed based on the EORTC
QLQ-C30. Moreover, clinical benefit (CB) was recorded in
all patients (Additional file 1).
Statistical analysis
Tumor response was defined as the primary endpoint of
the study. Secondary endpoints included PFS, OS, qual-
ity of life and clinical benefit. All patients treated for at
least one cycle of chemotherapy, even in case of protocol
violation, were included into final analysis on an
intention to treat (ITT) basis. The trial was based on a
Simon’s two-stage design [23]. For the sample size calcula-
tion a response rate of ≥15 % was considered sufficient in
an interim analysis, whereas a rate ≤5 % was insufficient.
The size of the type I (α) and II (β) errors were 0.1 and
0.2, respectively. An interim analysis was planned after 22
patients and in case of no response the study would be
closed prematurely. Otherwise another 22 patients were
to be enrolled until the total number of 44 participants
was reached. OS and PFS were estimated using the
Kaplan-Meier method. A descriptive data analysis was
done for EORTC-QLQ-C30 and clinical benefit. The
clinical benefit was calculated from four parameters (pain-
intensity, use of pain-medication, KPS and body-weight)
[24]. Pain intensity/use of analgetics and KPS were defined
as primary indicators, body weight counted as a secondary
indicator. For the evaluation of the clinical benefit patients
had either to be positive, stable or negative classified for
the primary indicators. Only in case of stable primary indi-
cators the secondary indicator, body weight, was included
for overall assessment. For positive evaluation of the clin-
ical benefit at least 4 weeks of improvement of the indica-
tors were required. A diagram for the assessment of the
clinical benefit is displayed in the (Additional file 2).
Results
Patients characteristics
A total of 47 patients were recruited between February
2008 and March 2012 at five German institutions. The
primary analysis was restricted to 44 patients (ITT-
population). Three patients did not start treatment due
to death (two patients) or refusal (one patient). The first
stage of the study included 22 patients for interim ana-
lysis. After fulfilling the preset requirements for proceed-
ing of the trial (response rate ≥15 %) another 22 patients
were enrolled. The patient characteristics are listed in
Table 1. As first line treatment all patients received a
gemcitabine-based regimen, except two patients who re-
ceived a 5-FU based concept. The median duration of first
line therapy was 4.5 months (2.1–7.25 months). The main
reasons for discontinuation of first line therapy were pro-
gressive disease in 42 patients (95.5 %) and toxicity in two
cases (4.5 %). Most of the patients (81.8 %, 36/44) had
metastatic disease at initiation of second line therapy.
Dose intensity and efficacy
In median 3 weeks passed between termination of the
first line therapy and start of the second line treat-
ment. From the ITT-population four patients (9.1 %)
received only 1 cycle, another twelve (27.3 %) only
2 cycles, respectively. The median number of chemo-
therapy cycles was 4 (range: 1–8 cycles). Nine
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patients (20.5 %) completed the pre-planned 8 cycles
of chemotherapy. Ten patients were eligible for final
staging by computed tomography after 8 cycles: two
had continuous partial response (PR), six stable dis-
ease (SD) and two progressive disease (PD). The final
analysis includes one patient with a total of 7 cycles
chemotherapy who refused the last cycle. Interest-
ingly, even after 8 cycles of treatment with DocOx, a
partial response was observed in two patients and
stable disease in another six patients corresponding a
disease control rate of 18 %.
The main reason for discontinuation of treatment
was PD in 28 cases (63.6 %) Toxicity and death were
in charge for therapy discontinuation each within
three cases (6.8 %). Seven patients (15.9 %) completed
the planned treatment of 8 cycles and four continued
therapy beyond the planned treatment period. The
median relative dose intensity for both drugs was
95.7 % of the theoretical dose for the applied cycles.
The dose intensity was slightly higher for docetaxel
compared to oxaliplatin (97.5 % vs. 93.5 %).
All patients had at least one measurable lesion for
response assessment. Seven patients exhibited a par-
tial response according to RECIST 1.0 (15.9 %, 95 %
CI 10–26 %, see Table 2). Stable disease was observed
in 14 patients (31.8 %). The calculated disease control
rate (DCR) was 47.7 %. The DCR was defined as the
proportion of patients with PR or SD for at least 2 -
cycles. The median PFS was 1.82 months (CI 95 %
1.5–3.96 months), Fig. 1. The PFS rate at 6 months
and 1 year was 17.1 % in both cases. The median OS
was 10.1 months (CI 95 % 5.1–14.1 months), Fig. 2.
OS rates were 56.8 % at 6 months and 39.3 % at
1 year, respectively. There is one exceptional long
time survivor with an overall survival of 75 months
from primary diagnosis and a PFS of 36 months after
start of second line treatment with a total of 22 cycles
of docetaxel/oxaliplatin.
Quality of life and clinical benefit
Quality of life (QoL) was assessed using the QLQ-
C30 questionnaire. A descriptive analysis revealed
relevant changes in quality of life. Interestingly, QoL
was independent from therapy response. The clinical
benefit was calculated from the four parameters pain-
intensity, use of analgesics, KPS and body-weight
according to Burris et al. [24] and as described above.
Five patients (11.4 %) described a clinical benefit (two
patients with a tumor response and three without
Table 1 Baseline Characteristics
Docetaxel/Oxaliplatin (n = 44)







Median (and range) 66.5 38–76
Karnofsky performance status score (n = 43)
100 % 9 20.9
90 % 21 48.8
80 % 13 30.2
Prior surgery
No 26 59

















Median duration of first line
therapy (mts)
4.5 95 % CI 2.1–7.25
amultiple presentations included; 95 % CI confidence interval
Table 2 Response and Survival
Docetaxel/Oxaliplatin (n = 44)
Efficacy Number of Patients Percent
Response
Complete response (CR) 0
Partial response (PR) 7 15.9
Stable disease (SD) 14 31.8
Progressive disease (PD) 23 52.3
Disease control rate
(CR + PR + SD)
21 47.7




Median overall survival 10.1 5.1–14.1
95 % CI confidence interval
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response) at different time points of study termin-
ation. In 39 cases (88.6 %) the score worsened. The
CB parameters are listed in Table 3. Pain intensity
was stable or decreased in the majority of patients
(90.2 %, 37/41) throughout the therapy. The KPS was
stable in 28 patients (63.6 %) during the course of
treatment. Any loss of body weight was noticed in 40
patients (90.9 %).
From the collected data for Global Health Status out
of the EORTC QLQ-C30 questionnaire we calculated
the median time until definitive deterioration (TUDD).
The TUDD was calculated in accordance to the pub-
lished papers of Anota et al. and Bonnetain
et al. and defined as an ongoing deterioration of at least
five points as compared to the baseline [25, 26]. The me-
dian TUDD was calculated with 3.5 months.
Safety
Treatment had to be discontinued in three patients
(6.8 %) due to hematologic toxicity. Table 4 summarizes
Fig. 1 Kaplan-Meier plot: second line progression free survival time with 95 % confidence interval. PFS progression free survival
Fig. 2 Kaplan-Meier plot: second line overall survival time with 95 % confidence interval. OS overall survival
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the most frequent adverse events. Neutropenia grade 3
to 4 occurred in 63.6 % (28/44) of patients. Febrile neu-
tropenia grade 3 to 4 was reported in 4.5 % (2/44) of
patients. However, only two patients (4.5 %) required
granulocyte-colony stimulating factor (G-CSF) at least
once during treatment. The major non-hematologic
grade 3 or 4 adverse events were diarrhea (11.4 %, 5/44)
and nausea (9.1 %, 4/44). Grade 1 or 2 peripheral neur-
opathy was reported in 52.3 % (23/44) of patients,
≥grade 3 in only one patient (2.3 %). The most common
grade 1 or −2 toxicities were alopecia (68.2 %, 30/44) and
mucositis (29.3 %, 13/44). A more detailed overview of the
toxicities is shown in the (Additional file 1: Table S1). No
unexpected toxicities were reported.
Discussion and conclusions
An increasing number of patients with PDAC are
eligible for a second line therapy. A recently published
systematic review found beneficial effects for second line
chemotherapies compared to best supportive care in
PDAC, in particular for combinations of platinum agents
and fluorouracil or gemcitabine [5]. However, there is
currently no standard of care in the second line setting
in PDAC. Evidence is mainly based on few small phase
II trials and one phase III trial [8, 9, 18, 27, 28]. The
CONKO-003 trial demonstrated that the combination of
oxaliplatin, 5-FU and leucovorin according to the OFF
regimen extends the duration of overall survival com-
pared to 5-FU alone or to best supportive care [8, 9].
This phase II trial was conducted to establish the
efficacy and safety of the combination of docetaxel
and oxaliplatin in the second line setting and its
impact on the quality of life and clinical benefit for
patients with advanced, chemorefractory PDAC. Both
substances have shown interesting response rates in
the first [12, 13] and second line [14, 15] setting in
metastatic PDAC as single agents or in combination.
Being aware of the limitations of a single arm trial the
combination of docetaxel/oxaliplatin achieved a re-
sponse rate of 15.9 %, a DCR of 47.7 %, a median OS
of 10.1 months (CI 95 % 5.1–14.1 months) and a me-
dian PFS of 1.82 months (CI 95 % 1.5–3.96 months).
These data are comparable to other published proto-
cols such as OFF (see Table 5). Interestingly, even after
8 cycles of treatment with DocOx, a partial response
was observed in two patients and stable disease in
another six patients corresponding to a disease control
rate of 18 %. There is one exceptional long time
survivor with an overall survival of 75 months from
primary diagnosis and a PFS of 36 months after start
of second line treatment with a total of 22 cycles of
docetaxel/oxaliplatin that is still alive.
In our study the combination of docetaxel/oxaliplatin
was in general well tolerated and no unexpected toxicities
occurred during therapy. Most subjects experienced at
least one grade 3/4 adverse event, mainly hematological
(neutropenia, 63.6 %) and diarrhea (11.4 %) see Table 4.
Compared to the OFF regimen [8, 9], the DocOx protocol
appears to be more toxic. However, all toxicities were
manageable. 15 patients (34.1 %) were still eligible to third
line therapy after progress to DocOx, see Table 6. The rate
of febrile neutropenia was low (<5 %) and only two
patients required single doses of G-CSF. A calcium and
magnesium infusion was applied at each cycle because at
the time the trial was conducted this was supposed to pre-
vent oxaliplatin-associated polyneuropathy [29]. However,
new data refute this concept [30].
There are few data on quality of life and clinical benefit
during second line treatment of patients with PDAC. For
the assessment of clinical benefit we used a composite
score of pain and analgesics requirements, Karnofsky
performance status, and body weight. In total five patients
Table 4 Common Grade 3 or 4 Adverse Events
Docetaxel/Oxaliplatin (n = 44)
Adverse Event Number of Patients Percent
Hematologic
Neutropenia 28 63.6







Peripheral Neuropathy 1 2.3
G-CSF use 2 4.5
G-CSF granulocyte-colony stimulating factor
Table 3 Clinical benefit
Docetaxel/Oxaliplatin (n = 44)
Number of Patients Percent 95 % CI
Clinical benefit response 5 11.4 3.79–24.56
Pain intensity (n = 41)
Decreased 4 9.8 2.72–23.13
Stable 29 70.7 54.46–83.87
Improved 8 19.5 8.82–34.87
Karnofsky Perfomance Score
Decreased 16 36.4 22.41–52.23
Stable 28 63.6 47.77–77.59
Body weight
Decreased 40 90.9 78.33–97.47
Increased 4 9.1 2.53–21.67
95 % CI confidence interval
Ettrich et al. BMC Cancer  (2016) 16:21 Page 6 of 9
(11.4 %) reported a clinical improvement at final examin-
ation. Cross trial comparisons to other second line trials
are difficult, due to different chemotherapy regimens,
heterogeneous patient collectives, distinct definitions of
clinical benefit and mostly due to the fact that only few
data are available. Recently, comparable results with an
improvement of clinical benefit in 20 % of patients were
reported in a phase II trial using nanoliposomal-irinotecan
as a single agent [27]. The median time until definitive
deterioration of the Global health status was calculated
with 3.5 months and is comparable to data from first line
settings published so far [25].
The major limitation of our data is the single arm
design. However, there was no established second line
chemotherapy available when this trial was initiated.
Furthermore, similar trials confirmed that patients
eligible for a second line treatment do not agree to be
randomized to best supportive care only [8]. The data
of this study compare well with those obtained with
other protocols including the OFF regimen (see
Table 5) and make this combination an option for
patients with chemorefractory PDAC.
A second limitation is the fact that by now a substantial
number of patients will have received oxaliplatin or a nab-
paclitaxel in the first line setting due to the increased use
of FOLFIRINOX or the gemcitabine/nab-paclitaxel regi-
men. However, a significant number of patients will still
receive gemcitabine +/− erlotinib in the first line setting
and could benefit from docetaxel/oxaliplatin as second
line treatment. Moreover, patients with an early relapse
after adjuvant gemcitabine therapy who are not eligible
for FOLFIRINOX maybe candidates for DocOx. In par-
ticular, the acceptable safety profile and the promising
data on efficacy, quality of life and clinical benefit make
this combination an interesting option for patients with
chemorefratory pancreatic cancer. Recently, single agent
nab-paclitaxel (phase II) [31] and the combination of
nano-liposomal irinotecan/ 5-FU/ LV (phase III) [10]
demonstrated promising results in this setting. It remains
Table 5 Second line therapies in advanced PDAC
Regimens Phase Patients mPFS (ms) mOS (ms) OS 6-ms % DCR % PR % Ref
FOLFIRINOX Ret 22 5.4 8.5 n.a. 63 19 [32] 2011
FOLFIRINOX Ret 18 2.8 8.4 44.4 55.6 27.8 [33] 2013
Nab-Paclitaxel II 19 1.7 7.3 58 37 5 [31] 2012
FOLFIRI II 50 3.2 5.0 32 36 8 [18] 2012
Capecitabine/Docetaxel II 43 3.7 5.3 n.a. 73 14 [34] 2014
mFOLFOX II 30 1.5 3.7 30 17 7 [28] 2009
FOLFIRI 31 2.1 4.2 27 23 0
OFF III 23 n.a. 4.8 n.a. n.a. n.a. [8] 2011
BSC 23 2.3
OFF III 76 2.9 5.9 n.a. n.a. n.a. [9] 2014
FF 84 2.0 3.3
Xelox II 39 2.5 5.8 44 28.6 2.6 [35] 2008
Docetaxel Ret 17 2 4 n.a. 35 6 [15] 2010
Nal-Iri II 40 2.4 5.2 42.5 50 7.5 [27] 2013
Nal-Iri/5-FU/LV III 417 3.1 6.1 n.a. n.a. n.a. [10] 2014
5-FU/LV 1.5 4.2
GEMOX II 33 4.2 6 n.a. 61.3 22.6 [36] 2006
Vatalanib II 67 2 n.a. 29 31 3 [37] 2014
DocOx II 44 1.8 10.1 56.8 48 15.9
mPFS median progression free survival time, mOS median overall survival time, Ref reference, Ret Retrospective, ms months, DCR disease control rate, PR partial
remission, ms months, OFF oxaliplatin, folinic acid, fluorouracil, LV leucovorine, 5-FU 5-fluorouracil, Nab-Paclitaxel nanoalbumine bound pacitaxel, Nal-Iri nanoliposomal
irinotecan, FOLFIRI fluorouracil, leucovorine, irinotecan, FOLFOX fluorouracil, leucovorine, oxaliplatin, FOLFIRINOX fluorouracil, leucovorine, irinotecan, oxaliplatin, DocOx
docetaxel oxaliplatin, n.a. not applicable, Ref Reference and publication date
Table 6 Third line therapies after failure of Docetaxel/Oxaliplatin
treatment
Third line therapy (n = 15)
Treatment Number of Patients Percent
Gemcitabine + Capecitabine 8 53.3
5-FU/Oxaliplatin based 3 20
5-FU/Irinotecan based 4 26.7
5-FU/Oxaliplatin based (OFF, FUFOX, XELOX, FOLFOX); 5-FU/Irinotecan based
(XELIRI, FOLFIRI)
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to be elucidated whether modern formulations of taxanes
or irinotecan are superior to docetaxel in this setting.
Additional files
Additional file 1: Table S1. Adverse Events independent from relation
to therapy. (DOCX 26.2 kb)
Additional file 2: Figure S1. Consort diagram. Figure S2. Flow chart
for the assessment of the clinical benefit. (DOCX 82.8 kb)
Abbreviations
BSC: best supportive care; CB: clinical benefit; CBC: complete blood count;
CI: confidence interval; CTC: common toxicity criteria; CTCAE: Common
Terminology Criteria for Adverse Events; DCR: disease control rate;
DocOx: docetaxel/oxaliplatin; ECG: electrocardiogram; ECOG: Eastern
Cooperative Oncology Group; EORTC: European Organization for Research
and Treatment of Cancer; 5-FU: 5-fluorouracil; FOLFIRINOX: fluorouracil
leucovorine, irinotecan, oxaliplatin; G-CSF: granulocyte-colony stimulating
factor; HR: hazard ratio; ITT: intention to treat; KPS: karnofsky performance
score; (m)OS: (median) overall survival; (m)PFS: (median) progression free
survival; NCI: National Cancer Institute; OFF: 5-FU leucovorin, oxaliplatin;
PD: progressive disease; PDAC: pancreatic ductal adenocarcinoma; PR: partial
response; QLQ-C30: quality of life questionnaire-core 30; QoL: quality of life;
RECIST: Response Evaluation Criteria in Solid Tumors; SAE: severe adverse
events; SD: stable disease; TUDD: time until definitive deterioration;
ULN: upper limit of normal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TJE, LP, MG, AWB, BD, RM have made substantial contributions to analysis
and interpretation of data. TS, GVW, VK have made substantial contributions
conception and design of the study. MG, PM, TMG, HFH, PBS have made
substantial contributions in the acquisition of data. TJE, LP, RM, TS have been
involved in drafting the manuscript. All authors gave final approval for the
version to be published.
Acknowledgements
Special thanks to Beate Einsiedler of the Institute of Epidemiology and
Medical Biometry, Ulm University for statistical support. The final results were
presented at the ASCO GI Cancer Symposium 2015 where the abstract was
awarded with a Merit Award by the Conquer Cancer Foundation of ASCO.
Funding
The trial was supported by Sanofi-Aventis.
Author details
1Department of Internal Medicine I, Ulm University, Albert-Einstein-Allee 23,
D-89081 Ulm, Germany. 2Department of Internal Medicine, Schön-Klinik
Hamburg-Eilbeck, Hamburg, Germany. 3Department of Gastroenterology,
Endocrinology, Metabolism and Infectiology, Philipps University of Marburg,
Marburg, Germany. 4Department of Internal Medicine I,
Martin-Luther-University, Halle (Saale), Germany. 5Department of Internal
Medicine, Stauferklinikum Schwaebisch-Gmuend, Mutlangen, Germany.
6Department of Internal Medicine, Oncology/Hematology, Gastroenterology,
Esslingen Hospital, Esslingen, Germany. 7Institute of Epidemiology and
Medical Biometry, Ulm University, Ulm, Germany. 8Praxis für Hämatologie
und Onkologie Ulm, Ulm, Germany.
Received: 28 July 2015 Accepted: 6 January 2016
References
1. Haberland J, Bertz J, Wolf U, Ziese T, Kurth BM. German cancer statistics
2004. BMC Cancer. 2010;10:52.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin.
2010;60:277–300.
3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al.
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J
Med. 2011;364:1817–25.
4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al.
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
N Engl J Med. 2013;369:1691–703.
5. Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF. Second-line
treatment in advanced pancreatic cancer: a comprehensive analysis of
published clinical trials. Ann Oncol. 2013.
6. Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic
adenocarcinoma. World J Gastroenterol. 2015;21:9297–316.
7. Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy
regimens for advanced pancreatic cancer: a systematic review and network
meta-analysis. BMC Cancer. 2014;14:471.
8. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dorken B, et al. Best
supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF)
plus BSC in patients for second-line advanced pancreatic cancer: a phase III-
study from the German CONKO-study group. Eur J Cancer. 2011;47:1676–81.
9. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line
oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil
alone for gemcitabine-refractory pancreatic cancer: outcomes from the
CONKO-003 trial. J Clin Oncol. 2014;32:2423–9.
10. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic
pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a
global, randomised, open-label, phase 3 trial. Lancet. 2015 Nov 29, [Epub
ahead of print]
11. Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, et al. A prognostic model to
identify patients with advanced pancreas adenocarcinoma who could benefit
from second-line chemotherapy. Clin Oncol (R Coll Radiol). 2012;24:105–11.
12. Lenzi R, Yalcin S, Evans DB, Abbruzzese JL. Phase II study of docetaxel in
patients with pancreatic cancer previously untreated with cytotoxic
chemotherapy. Cancer Invest. 2002;20:464–72.
13. Rougier P, Adenis A, Ducreux M, de Forni M, Bonneterre J, Dembak M, et al.
A phase II study: docetaxel as first-line chemotherapy for advanced
pancreatic adenocarcinoma. Eur J Cancer. 2000;36:1016–25.
14. Cereda S, Reni M. Weekly docetaxel as salvage therapy in patients with
gemcitabine-refractory metastatic pancreatic cancer. J Chemother.
2008;20:509–12.
15. Saif MW, Syrigos K, Penney R, Kaley K. Docetaxel second-line therapy in
patients with advanced pancreatic cancer: a retrospective study. Anticancer
Res. 2010;30:2905–9.
16. Berk V, Ozdemir N, Ozkan M, Aksoy S, Turan N, Inal A, et al. XELOX vs.
FOLFOX4 as second line chemotherapy in advanced pancreatic cancer.
Hepatogastroenterology. 2012;59:2635–9.
17. El-Hadaad HA, Wahba HA. Oxaliplatin plus 5-fluorouracil and folinic acid
(OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II
study. J Gastrointest Cancer. 2013;44:313–7.
18. Zaniboni A, Aitini E, Barni S, Ferrari D, Cascinu S, Catalano V, et al. FOLFIRI as
second-line chemotherapy for advanced pancreatic cancer: a GISCAD
multicenter phase II study. Cancer Chemother Pharmacol. 2012;69:1641–5.
19. Kouroussis C, Agelaki S, Mavroudis D, Kakolyris S, Androulakis N, Kalbakis K,
et al. A dose escalation study of docetaxel and oxaliplatin combination in
patients with metastatic breast and non-small cell lung cancer. Anticancer
Res. 2003;23:785–91.
20. Raez LE, Santos ES, Lopes G, Rosado MF, Negret LM, Rocha-Lima C, et al.
Efficacy and safety of oxaliplatin and docetaxel in patients with locally
advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer.
2006;53:347–53.
21. Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, et al.
Results of docetaxel plus oxaliplatin (DOCOX) +/− cetuximab in patients
with metastatic gastric and/or gastroesophageal junction adenocarcinoma:
results of a randomised Phase 2 study. Eur J Cancer. 2013;49:2823–31.
22. NCT00690300. Docetaxel plus Oxaliplatin as Therapy in Patients With
Pancreatic Cancer. ClinicalTrials.gov 2008.
23. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin
Trials. 1989;10:1–10.
24. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML,
Modiano MR, et al. Improvements in survival and clinical benefit with
gemcitabine as first-line therapy for patients with advanced pancreas
cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.
Ettrich et al. BMC Cancer  (2016) 16:21 Page 8 of 9
25. Bonnetain F, Dahan L, Maillard E, Ychou M, Mitry E, Hammel P, et al. Time
until definitive quality of life score deterioration as a means of longitudinal
analysis for treatment trials in patients with metastatic pancreatic
adenocarcinoma. Eur J Cancer. 2010;46:2753–62.
26. Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier
P, et al. Time to health-related quality of life score deterioration as a
modality of longitudinal analysis for health-related quality of life studies in
oncology: do we need RECIST for quality of life to achieve standardization?
Qual Life Res. 2015;24:5–18.
27. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, et al. A multinational
phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for
patients with gemcitabine-refractory metastatic pancreatic cancer. Br J
Cancer. 2013;109:920–5.
28. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised
phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line
therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Br J Cancer. 2009;101:1658–63.
29. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T,
et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory
neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol.
2011;29:421–7.
30. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al.
Phase III randomized, placebo-controlled, double-blind study of intravenous
calcium and magnesium to prevent oxaliplatin-induced sensory
neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014;32:997–1005.
31. Hosein PJ, de Lima Lopes G, Jr., Pastorini VH, Gomez C, Macintyre J, Zayas G,
et al. A phase II trial of nab-Paclitaxel as second-line therapy in patients with
advanced pancreatic cancer. Am J Clin Oncol. 2013 Apr; 36(2):151-6.
32. Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D,
et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin
(FOLFIRINOX) as second-line chemotherapy in patients with metastatic
pancreatic adenocarcinoma. Oncology. 2011;80:301–6.
33. Lee MG, Lee SH, Lee SJ, Lee YS, Hwang JH, Ryu JK, et al. 5-Fluorouracil/
leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as
second-line chemotherapy in patients with advanced pancreatic cancer
who have progressed on gemcitabine-based therapy. Chemotherapy.
2013;59:273–9.
34. Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, et al. A
phase II study of capecitabine plus docetaxel in gemcitabine-pretreated
metastatic pancreatic cancer patients: CapTere. Cancer Chemother
Pharmacol. 2014;73:839–45.
35. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA.
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy
for patients with advanced pancreatic cancer. Cancer. 2008;113:2046–52.
36. Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, et al.
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced
pancreatic adenocarcinoma: a phase II study. Br J Cancer. 2006;94:481–5.
37. Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, et al. Phase II
trial of vatalanib in patients with advanced or metastatic pancreatic
adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer
Chemother Pharmacol. 2014;74:379–87.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ettrich et al. BMC Cancer  (2016) 16:21 Page 9 of 9
